CA3229274A1 - Methods and compositions for treating fibrotic liver conditions, using udenafil compositions - Google Patents

Methods and compositions for treating fibrotic liver conditions, using udenafil compositions Download PDF

Info

Publication number
CA3229274A1
CA3229274A1 CA3229274A CA3229274A CA3229274A1 CA 3229274 A1 CA3229274 A1 CA 3229274A1 CA 3229274 A CA3229274 A CA 3229274A CA 3229274 A CA3229274 A CA 3229274A CA 3229274 A1 CA3229274 A1 CA 3229274A1
Authority
CA
Canada
Prior art keywords
liver
patient
fibrotic
elf
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3229274A
Other languages
English (en)
French (fr)
Inventor
David J. GOLDBERG
Mark W. RUSSELL
Kurt R. SCHUMACHER
James L. Yeager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mezzion Pharma Co Ltd
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of CA3229274A1 publication Critical patent/CA3229274A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3229274A 2021-08-13 2022-08-12 Methods and compositions for treating fibrotic liver conditions, using udenafil compositions Pending CA3229274A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163233133P 2021-08-13 2021-08-13
US63/233,133 2021-08-13
PCT/US2022/040227 WO2023018972A1 (en) 2021-08-13 2022-08-12 Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Publications (1)

Publication Number Publication Date
CA3229274A1 true CA3229274A1 (en) 2023-02-16

Family

ID=83355014

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3229274A Pending CA3229274A1 (en) 2021-08-13 2022-08-12 Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Country Status (7)

Country Link
US (2) US20230218622A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384176A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532957A (cg-RX-API-DMAC7.html)
AU (1) AU2022325803A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229274A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001972A (cg-RX-API-DMAC7.html)
WO (1) WO2023018972A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12396708B2 (en) * 2024-01-08 2025-08-26 Echosens Sa Method for determining an index for assessing a cardiac function of a subject
EP4582017A1 (en) * 2024-01-08 2025-07-09 Echosens Method for determining an index for assessing a cardiac function of a subject

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
EP1888074B1 (en) * 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
MX390977B (es) 2014-08-12 2025-03-21 Mezzion Pharma Co Ltd Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo

Also Published As

Publication number Publication date
EP4384176A1 (en) 2024-06-19
MX2024001972A (es) 2024-11-08
JP2024532957A (ja) 2024-09-10
WO2023018972A1 (en) 2023-02-16
US20230218622A1 (en) 2023-07-13
US20250186448A1 (en) 2025-06-12
AU2022325803A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US20250186448A1 (en) Formulations of udenafil
JP2025032254A (ja) ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法
US12576081B2 (en) Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions
US20220047678A1 (en) Combination Therapy for Treatment of Liver Disease
US20240285630A1 (en) Methods and compositions for improving exercise performance
HK1236115A (en) Methods of improving myocardial performance in fontan patients using udenafil compositions

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240812

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240812